U.S. Markets open in 6 hrs 32 mins

Alkermes plc (ALKS)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
57.99-0.64 (-1.09%)
At close: 4:00PM EDT
People also watch
ALXNBMRNNBIXINCYVRTX

Alkermes plc

Connaught House
1 Burlington Road
Dublin 4
Ireland
353 1 772 8000
http://www.alkermes.com

SectorHealthcare
IndustryDrug Delivery
Full Time Employees1,750

Key Executives

NameTitlePayExercisedAge
Mr. Richard F. PopsChairman and Chief Exec. Officer2.57M6.43M55
Mr. Shane Martin CookePres1.31MN/A55
Dr. Floyd E. Bloom M.D.Co-Founder and Director85.5kN/A80
Mr. James M. FratesChief Financial Officer, Sr. VP and Treasurer876.25k2.57M50
Ms. Kathryn L. BibersteinChief Admin. Officer, Chief Compliance Officer, Chief Risk Officer, EVP and Sec.1.08M1.66M58
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company’s marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate Governance

Alkermes plc’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 6; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.